File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome

TitleMolecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome
Authors
Keywordsmyelodysplastic syndromes
hypomethylating agents
treatment resistance
targeted therapy
immunotherapy
Issue Date2021
PublisherMolecular Diversity Preservation International. The Journal's web site is located at http://www.mdpi.org/ijms
Citation
International Journal of Molecular Sciences, 2021, v. 22 n. 19, p. article no. 10232 How to Cite?
AbstractMyelodysplastic syndrome (MDS) is a heterogeneous, clonal hematological disorder characterized by ineffective hematopoiesis, cytopenia, morphologic dysplasia, and predisposition to acute myeloid leukemia (AML). Stem cell genomic instability, microenvironmental aberrations, and somatic mutations contribute to leukemic transformation. The hypomethylating agents (HMAs), azacitidine and decitabine are the standard of care for patients with higher-risk MDS. Although these agents induce responses in up to 40–60% of patients, primary or secondary drug resistance is relatively common. To improve the treatment outcome, combinational therapies comprising HMA with targeted therapy or immunotherapy are being evaluated and are under continuous development. This review provides a comprehensive update of the molecular pathogenesis and immune-dysregulations involved in MDS, mechanisms of resistance to HMA, and strategies to overcome HMA resistance.
Persistent Identifierhttp://hdl.handle.net/10722/305844
ISSN
2023 Impact Factor: 4.9
2023 SCImago Journal Rankings: 1.179
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLEE, P-
dc.contributor.authorYim, R-
dc.contributor.authorYung, Y-
dc.contributor.authorChu, HT-
dc.contributor.authorYip, PK-
dc.contributor.authorGill, H-
dc.date.accessioned2021-10-20T10:15:08Z-
dc.date.available2021-10-20T10:15:08Z-
dc.date.issued2021-
dc.identifier.citationInternational Journal of Molecular Sciences, 2021, v. 22 n. 19, p. article no. 10232-
dc.identifier.issn1661-6596-
dc.identifier.urihttp://hdl.handle.net/10722/305844-
dc.description.abstractMyelodysplastic syndrome (MDS) is a heterogeneous, clonal hematological disorder characterized by ineffective hematopoiesis, cytopenia, morphologic dysplasia, and predisposition to acute myeloid leukemia (AML). Stem cell genomic instability, microenvironmental aberrations, and somatic mutations contribute to leukemic transformation. The hypomethylating agents (HMAs), azacitidine and decitabine are the standard of care for patients with higher-risk MDS. Although these agents induce responses in up to 40–60% of patients, primary or secondary drug resistance is relatively common. To improve the treatment outcome, combinational therapies comprising HMA with targeted therapy or immunotherapy are being evaluated and are under continuous development. This review provides a comprehensive update of the molecular pathogenesis and immune-dysregulations involved in MDS, mechanisms of resistance to HMA, and strategies to overcome HMA resistance.-
dc.languageeng-
dc.publisherMolecular Diversity Preservation International. The Journal's web site is located at http://www.mdpi.org/ijms-
dc.relation.ispartofInternational Journal of Molecular Sciences-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectmyelodysplastic syndromes-
dc.subjecthypomethylating agents-
dc.subjecttreatment resistance-
dc.subjecttargeted therapy-
dc.subjectimmunotherapy-
dc.titleMolecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome-
dc.typeArticle-
dc.identifier.emailYim, R: ritayim@hku.hk-
dc.identifier.emailGill, H: gillhsh@hku.hk-
dc.identifier.authorityGill, H=rp01914-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/ijms221910232-
dc.identifier.pmid34638574-
dc.identifier.pmcidPMC8508686-
dc.identifier.scopuseid_2-s2.0-85115424129-
dc.identifier.hkuros326784-
dc.identifier.volume22-
dc.identifier.issue19-
dc.identifier.spagearticle no. 10232-
dc.identifier.epagearticle no. 10232-
dc.identifier.isiWOS:000706938900001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats